| Assessment Status |
Rapid Review Complete |
| HTA ID |
23024 |
| Drug |
Isatuximab |
| Brand |
Sarclisa® |
| Indication |
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Rapid review commissioned |
09/05/2023 |
| Rapid review completed |
25/05/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of isatuximab in combination with carfilzomib and dexamethasone compared with the current standard of care. |
